HUP0303379A2 - Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303379A2
HUP0303379A2 HU0303379A HUP0303379A HUP0303379A2 HU P0303379 A2 HUP0303379 A2 HU P0303379A2 HU 0303379 A HU0303379 A HU 0303379A HU P0303379 A HUP0303379 A HU P0303379A HU P0303379 A2 HUP0303379 A2 HU P0303379A2
Authority
HU
Hungary
Prior art keywords
acid
biologically active
compounds
sensitive
sensitive compounds
Prior art date
Application number
HU0303379A
Other languages
English (en)
Inventor
Michel Bessodes
Christophe Masson
Daniel Scherman
Barbara Wetzer
Original Assignee
Gencell S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0011278A external-priority patent/FR2813605B1/fr
Application filed by Gencell S.A. filed Critical Gencell S.A.
Publication of HUP0303379A2 publication Critical patent/HUP0303379A2/hu
Publication of HUP0303379A3 publication Critical patent/HUP0303379A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Polyethers (AREA)

Abstract

A találmány tárgyát képezik új savérzékeny vegyületek, amelyektartalmaznak (a) legalább egy hidrofil szubsztituenst a polialkilén-glikolok, mono- vagy poliszacharidok, hidrofil terápiás molekulák,vagy poliamin típusú csoportok közül választva és (b) egy ciklikusorto-észtert, és ezek sóit. A savérzékeny vegyületek részletesebben(I) általános képlettel írhatók le, ahol a képletben g jelentése 0, 1,2, 3 vagy 4 és G jelentése például hidrogénatom, egyenes vagy elágazóláncú, telített vagy telítetlen, 1-6 szénatomos alkilcsoport, vagy egyarilcsoport lehet. A találmány szerinti vegyületek alkalmazhatókbiológiailag aktív vegyületekkel képzett konjugátumok (liposzómák,komplexek, nanorészecskék és hasonlók) előállítására, amelykonjugátumokból a biológiailag aktív vegyület savas pH-jú szövetekbenvagy sejtszervekben felszabadul, vagy nemionos felületaktív anyagkéntbiológiailag aktív anyagokat tartalmazó részecskék stabilizálásáramajd savas közegben történő destabilizálására, vagy még másképp egyterápiás vegyülethez kovalensen hozzákapcsolt vektorként. A találmánytárgyai továbbá a legalább egy biológiailag aktív hatóanyagot és egyfentiek szerinti savérzékeny vegyületet tartalmazó készítmények;valamint a savérzékeny vegyületek gyógyszerként történő alkalmazásra. Ó
HU0303379A 2000-09-05 2001-09-03 Acid-sensitive compounds, use thereof and pharmaceutical compositions containing them HUP0303379A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0011278A FR2813605B1 (fr) 2000-09-05 2000-09-05 Composes acidosensibles, leur preparation et utilisations
US23911600P 2000-10-11 2000-10-11
PCT/FR2001/002725 WO2002020510A1 (fr) 2000-09-05 2001-09-03 Composes acidosensibles, leur preparation et utilisations

Publications (2)

Publication Number Publication Date
HUP0303379A2 true HUP0303379A2 (hu) 2004-01-28
HUP0303379A3 HUP0303379A3 (en) 2004-03-01

Family

ID=26212598

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303379A HUP0303379A3 (en) 2000-09-05 2001-09-03 Acid-sensitive compounds, use thereof and pharmaceutical compositions containing them

Country Status (13)

Country Link
US (1) US20050085426A1 (hu)
EP (1) EP1317439B1 (hu)
JP (1) JP2004508364A (hu)
KR (1) KR20030040441A (hu)
CN (1) CN1452617A (hu)
AT (1) ATE312088T1 (hu)
AU (1) AU2001287801A1 (hu)
CA (1) CA2421179A1 (hu)
DE (1) DE60115667T2 (hu)
HU (1) HUP0303379A3 (hu)
IL (1) IL154736A0 (hu)
MX (1) MXPA03001876A (hu)
WO (1) WO2002020510A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338789T3 (es) 2003-06-18 2010-05-12 Tranzyme Pharma Inc. Antagonistas macrociclicos del receptor de motilina.
FR2925491B1 (fr) * 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
KR101014246B1 (ko) 2008-07-03 2011-02-16 포항공과대학교 산학협력단 페하 민감성 금속 나노 입자 및 이의 제조 방법.
GB201307438D0 (en) * 2013-04-25 2013-06-05 Airbus Uk Ltd Fuel Additive
KR101725240B1 (ko) 2015-03-24 2017-04-11 부산대학교 산학협력단 UV-광 반응성 및 pH 반응성을 갖는 이중 자극 반응성 코어-쉘 자성나노입자 및 이를 포함하는 약물 전달체
EP3095790A1 (en) 2015-05-22 2016-11-23 Universite De Bordeaux Nucleoside-lipid compounds with ph-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent
CN111771114A (zh) * 2018-02-26 2020-10-13 沃特世科技公司 对酸不稳定的表面活性剂及用于执行蛋白质溶解或酶消化的方法
CN116656706A (zh) * 2023-04-18 2023-08-29 河南中医药大学第一附属医院 一种酸敏融合蛋白重组质粒及其构建、应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4406686A (en) * 1981-07-24 1983-09-27 Stauffer Chemical Company Haloalkylaminomethyldioxolane herbicide antidotes
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations

Also Published As

Publication number Publication date
WO2002020510A1 (fr) 2002-03-14
MXPA03001876A (es) 2004-09-10
CN1452617A (zh) 2003-10-29
JP2004508364A (ja) 2004-03-18
DE60115667D1 (de) 2006-01-12
KR20030040441A (ko) 2003-05-22
EP1317439B1 (fr) 2005-12-07
CA2421179A1 (en) 2002-03-14
IL154736A0 (en) 2003-10-31
AU2001287801A1 (en) 2002-03-22
EP1317439A1 (fr) 2003-06-11
US20050085426A1 (en) 2005-04-21
ATE312088T1 (de) 2005-12-15
HUP0303379A3 (en) 2004-03-01
DE60115667T2 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
FI940115A (fi) Nanokapseleita sisältävät farmaseuttiset seokset
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
SE0102438D0 (sv) New compounds
RU94045798A (ru) Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и способ получения, фармацевтическая композиция на их основе и ее получение, способ получения водных растворов с повышенной концентрацией итраконазола или саперконазола
HUP0303868A2 (hu) Helyettesített triazol-diamin-származékok mint kináz inhibitorok és alkalmazások gyógyszerkészítmények előállítására
DE3853579D1 (de) Tri-azamakrozyklen und deren metall komplexe.
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
NO20032829D0 (no) Kjemiske forbindelser
ATE316083T1 (de) Adamantanderivate
ATE310506T1 (de) Biodegradierbare polyphosphoester- zusammensetzungen zur behandlung von ovarialkrebs
ME00467B (me) 13-točlani azalidi i njihova primena kao antibiotičkih sredstava
YU2703A (sh) Bistar vodeni anestetski preparat
HUP0102515A2 (hu) Ciklopeptidek, eljárás előállításukra, hatóanyagként azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0004071A2 (hu) Prosztaglandin-származékokat tartalmazó gyógyszerkészítmények
HUP0303379A2 (hu) Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0204563A2 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
ATE316086T1 (de) Clathrat von azithromycin-hydrat mit 1,2- propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
TNSN06142A1 (en) Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
HUP0303195A2 (hu) O-helyettesített-6-metil-tramadol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
FR2869611A1 (fr) Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
BR0109617A (pt) Composição farmacêutica, oligossacarìdeo, processo de preparação de oligossacarìdeos, e, utilização de oligossacarìdeos

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees